|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net sales | |||||
| Cost of sales | |||||
| Gross profit | |||||
| Selling, general and administrative expenses | |||||
| Restructuring and other similar charges | |||||
| Loss on divestiture of asbestos liabilities and certain assets | |||||
| Amortization of intangible assets | |||||
| Income from operations | |||||
| Non-operating expense: | |||||
| Interest expense, net | |||||
| Loss on the extinguishment of debt | |||||
| Actuarial gain on pension and other postretirement benefit obligations | |||||
| Other income (expense), net | |||||
| Income before income taxes | |||||
| Provision for income taxes | |||||
| Net income from continuing operations | |||||
| Income from discontinued operations, net of tax | |||||
| Net income | |||||
| Basic net income per share: | |||||
| Continuing operations (in dollars per share) | |||||
| Discontinued operations (in dollars per share) | |||||
| Net income (in dollars per share) | |||||
| Diluted net income per share: | |||||
| Continuing operations (in dollars per share) | |||||
| Discontinued operations (in dollars per share) | |||||
| Net income (in dollars per share) | |||||
| Weighted-average number of common shares outstanding (in thousands): | |||||
| Basic (in shares) | |||||
| Effect of dilutive equity awards (in shares) | |||||
| Diluted (in shares) | |||||
Loading...